Pharmacogenetic Risk for Adverse Reactions to Irinotecan in the Major Ethnic Populations of Singapore
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenetic Risk for Adverse Reactions to Irinotecan in the Major Ethnic Populations of Singapore
Authors
Keywords
-
Journal
DRUG SAFETY
Volume 34, Issue 12, Pages 1167-1175
Publisher
Springer Nature
Online
2011-11-12
DOI
10.2165/11594440-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regimen Selection for First-line FOLFIRI and FOLFOX Based on UGT1A1 Genotype and Physical Background is Feasible in Japanese Patients with Advanced Colorectal Cancer
- (2011) H. Ishida et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
- (2010) Yu Sunakawa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan
- (2010) J. M. van der Bol et al. CLINICAL CANCER RESEARCH
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
- (2010) Zhe-Yi Hu et al. EUROPEAN JOURNAL OF CANCER
- Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments
- (2010) Jieming Chen et al. PHARMACOGENOMICS
- Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer
- (2009) Heather Taffet Gold et al. CANCER
- Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
- (2009) GENETICS IN MEDICINE
- Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
- (2009) Glenn E Palomaki et al. GENETICS IN MEDICINE
- Singapore Genome Variation Project: A haplotype map of three Southeast Asian populations
- (2009) Y.-Y. Teo et al. GENOME RESEARCH
- UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
- (2009) Masahide Onoue et al. International Journal of Clinical Oncology
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
- (2009) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- UGT1A1 Haplotype Mutation among Asians in Singapore
- (2009) Y.Y. Zhou et al. Neonatology
- UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
- (2008) D M Kweekel et al. BRITISH JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started